SCHEDULE 13D: Soleus Capital Urges ESSA Pharma to Liquidate and Return Cash to Shareholders

Soleus Capital, a significant shareholder in ESSA Pharma, Inc., has filed a Schedule 13D to advocate for the company to wind down operations and distribute its cash to shareholders, citing the current share price being significantly below its cash per share.

Summary

• Soleus Capital Master Fund, L.P. and its affiliated entities (collectively, "Soleus Capital") have filed a Schedule 13D, superseding their previous Schedule 13G, indicating a change from a passive investment stance to an active one.
• Soleus Capital beneficially owns 2,262,026 shares of ESSA Pharma, Inc. Common Stock, representing approximately 5.1% of the outstanding shares.
• The reporting persons initially invested in ESSA Pharma on August 27, 2019, purchasing 1,250,000 shares of Common Stock and 5,000,000 pre-funded warrants for an aggregate of $12.5 million.
• Soleus Capital has engaged, and intends to continue engaging, in discussions with ESSA Pharma's Board of Directors and management regarding opportunities to enhance stockholder value, specifically proposing the winding down and liquidation of the Issuer to distribute remaining cash to shareholders.
• On April 15, 2025, Soleus Capital sent a letter to the Board highlighting that ESSA Pharma's share price, currently around $1.60, is significantly below its roughly $2.40 of cash per share.
• The reporting persons believe that liquidating the company and returning cash to shareholders is in the best interests of shareholders due to the current valuation disparity.

Sentiment

Score: 4

Explanation: The sentiment is mixed. While the activist investor praises management's past stewardship, the core message is a strong negative assessment of the company's current valuation and future prospects, leading to a call for liquidation. This indicates a lack of confidence in the current strategic path to create value beyond cash.

Positives

• Soleus Capital acknowledges ESSA Pharma's management as "exemplary stewards of investors capital," having efficiently executed clinical studies and demonstrated a commitment to transparency.
• The company's dedication to serving patients and shareholders is highlighted as a benchmark for the industry by Soleus Capital.
• The activist stance by Soleus Capital could potentially unlock shareholder value by forcing a liquidation or other strategic action that closes the gap between share price and cash per share.

Negatives

• The company's share price of approximately $1.60 is significantly below its cash per share of roughly $2.40, indicating a substantial undervaluation by the market.
• Soleus Capital expressed disappointment over last year's EPI-7386 results, which led to the halting of clinical studies and the pursuit of strategic alternatives.
• The call for liquidation suggests a lack of confidence from a major shareholder in the company's ability to create value through its ongoing operations or strategic alternatives, beyond its current cash holdings.

Risks

• Risk of continued value erosion if the company does not pursue the liquidation strategy advocated by Soleus Capital.
• The failure of the EPI-7386 clinical trial results has already impacted the company's strategic direction and valuation.
• Uncertainty regarding the outcome of discussions between Soleus Capital and ESSA Pharma's Board of Directors regarding the proposed liquidation.

Future Outlook

Soleus Capital intends to continue reviewing its investment in ESSA Pharma and may increase or decrease its holdings based on market conditions, company developments, and other factors. Their primary forward-looking proposal is for ESSA Pharma to wind down operations and distribute its remaining cash to shareholders.

Management Comments

• "The Company has been exemplary stewards of investors capital, efficiently executing clinical studies that answered key scientific questions."
• "Though we shared in the disappointment over last years EPI-7386 results, we supported the Companys decision to halt clinical studies and pursue strategic alternatives."
• "Its commitment to transparency and dedication to serving patients and shareholders alike stands as a benchmark for the entire industry."
• "The Companys share price, currently around $1.60, is significantly below its roughly $2.40 of cash per share."
• "While we support managements thoughtful evaluation of various strategic paths, we now believe it is in shareholders best interest for the Company to wind down operations and return remaining cash to shareholders, and we urge you to take action to do so."

Industry Context

This filing highlights a common scenario in the biotechnology sector where clinical trial failures can lead to significant market cap erosion, sometimes below the company's cash value. Activist investors often step in to advocate for liquidation or significant strategic shifts to unlock this 'cash discount.' This situation reflects broader macroeconomic pressures placing a higher premium on cash and liquidity for investors, especially in sectors with high R&D risk.

Comparison to Industry Standards

• The situation where a company's market capitalization falls significantly below its net cash position is not uncommon in the biotech industry, particularly after major clinical setbacks like the EPI-7386 results mentioned.
• Companies such as Aileron Therapeutics (ALRN) or Sierra Oncology (SRRA) in the past have faced similar pressures, with investors advocating for liquidation or asset sales when their market value dipped below cash.
• Soleus Capital's approach of advocating for a wind-down and cash distribution is a standard activist strategy employed when a company's core business prospects are dim and its cash balance represents a significant portion of its perceived value, offering a potential arbitrage opportunity for investors.

Stakeholder Impact

• Shareholders: Potential for a return of capital if liquidation occurs, which could be higher than the current share price. However, it also means the end of the company's operations and future growth potential.
• Employees: A wind-down and liquidation would likely result in job losses.
• Patients: The cessation of drug development activities would impact patients who might have benefited from ESSA Pharma's therapies.
• Management: Their strategic direction is being challenged by a major shareholder, potentially leading to significant changes in company operations or leadership.

Next Steps

• Soleus Capital intends to continue engaging in communications with ESSA Pharma's Board of Directors and management.
• Soleus Capital may decide to increase or decrease its investment in ESSA Pharma based on market conditions and company developments.
• ESSA Pharma's Board of Directors is urged by Soleus Capital to take action to wind down operations and return remaining cash to shareholders.

Key Dates

Recommendation

Keywords

ESSA Pharma, Soleus Capital, Schedule 13D, Activist Investor, Shareholder Value, Liquidation, Cash Per Share, Prostate Cancer, Biotechnology, SEC Filing